Stockreport

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech, Inc. - Common Shares  (EDSA) 
PDF Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorb [Read more]